Xocova (ensitrelvir) / Shionogi  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xocova (ensitrelvir) / Shionogi
SCORPIO-HR, NCT05305547: A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19

Completed
3
2093
Europe, Japan, US, RoW
S-217622, Placebo
Shionogi, National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV-2 Infection
01/24
05/24
SCORPIO-PEP, NCT05897541: Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection

Recruiting
3
2200
Japan, US
S-217622, Placebo
Shionogi
SARS-CoV-2 Infection
09/24
09/24
NCT05605093: Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

Recruiting
3
1500
Europe, Japan, US, RoW
Shionogi Protease Inhibitor (S-217622), ensitrelvir, placebo
University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
07/25
07/25

Download Options